Glutamatergic Dysregulation in Schizophrenia Models

Glutamate, the principal excitatory neurotransmitter in the mammalian brain, orchestrates synaptic transmission and plasticity through ionotropic receptors such as N-methyl-D-aspartate receptors (NMDARs) and α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors (AMPARs). In schizophrenia models, a consistent theme is hypofunction of NMDARs on distinct neuronal populations, leading to disrupted excitatory–inhibitory balance, impaired long-term potentiation and aberrant network oscillations. Genetic manipulations of NMDAR subunits or associated scaffolding proteins recapitulate cognitive deficits and abnormal attentional salience, while pharmacological blockade of NMDARs induces a spectrum of psychosis-like phenotypes. Parallel lines of investigation have revealed that metabolic enzymes governing glutamate availability, such as glutamate dehydrogenase 1, modulate cortical glutamate tone and interact with environmental stressors to precipitate enduring prefrontal dysfunction. Dysregulated AMPAR trafficking and phosphorylation further compound synaptic deficits, impairing hippocampal-dependent learning and working memory. Together, these preclinical models map a trajectory from molecular disruption of glutamatergic signalling to circuit-level disturbances and behavioural impairments, informing both mechanistic insight and therapeutic strategies aimed at restoring synaptic homeostasis.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Glutamatergic Dysregulation in Schizophrenia Models publication trend

The graph below shows the total number of articles in glutamatergic dysregulation in schizophrenia models across all publications each year (not limited to Nature Index journals).

Technical terms

N-methyl-D-aspartate receptor (NMDAR): A calcium-permeable ionotropic glutamate receptor critical for synaptic plasticity and memory formation.

α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR): A fast excitatory glutamate receptor that mediates the majority of rapid synaptic transmission.

Synaptic plasticity: The activity-dependent modification of synaptic strength, encompassing processes such as long-term potentiation and depression.

Long-term potentiation (LTP): A sustained increase in synaptic efficacy following high-frequency stimulation, regarded as a cellular correlate of learning and memory.

Glutamate dehydrogenase 1 (Glud1): A mitochondrial enzyme that regulates glutamate metabolism and contributes to the control of neurotransmitter pools.

References

1. GRIN2A (NR2A): a gene contributing to glutamatergic involvement in schizophrenia. Molecular Psychiatry (2023).
2. Synergistic, long-term effects of glutamate dehydrogenase 1 deficiency and mild stress on cognitive function and mPFC gene and miRNA expression. Translational Psychiatry (2023).
3. Novel α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptor (AMPAR) potentiator LT‐102: A promising therapeutic agent for treating cognitive impairment associated with schizophrenia. CNS Neuroscience & Therapeutics (2024).
4. NMDAR Hypofunction Animal Models of Schizophrenia. Frontiers in Molecular Neuroscience (2019).